Ken Griffin Repare Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$3.02 - $4.7 $6,644 - $10,340	-2,200 Reduced 56.41%	1,700 $5,000
Q1 2024 May 15, 2024	SELL	$4.53 - $8.41 $52,548 - $97,556	-11,600 Reduced 74.84%	3,900 $18,000
Q4 2023 Feb 14, 2024	SELL	$3.22 - $11.79 $2,576 - $9,432	-800 Reduced 4.91%	15,500 $113,000
Q3 2023 Nov 14, 2023	BUY	$8.16 - $13.01 $70,992 - $113,187	8,700 Added 114.47%	16,300 $196,000
Q1 2023 May 15, 2023	SELL	$9.32 - $15.06 $42,872 - $69,276	-4,600 Reduced 37.7%	7,600 $74,000
Q4 2022 Feb 14, 2023	SELL	$12.5 - $18.13 $1.14 Million - $1.65 Million	-90,800 Reduced 88.16%	12,200 $179,000
Q3 2022 Nov 14, 2022	SELL	$11.57 - $15.59 $71,734 - $96,658	-6,200 Reduced 5.68%	103,000 $1.25 Million

35.4M

50K

300

Ticker RPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,937,800
Market Cap $118M
Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.